CA1263316A - Medical composition for injection containing a spergualin as active ingredient and process for preparing the same - Google Patents

Medical composition for injection containing a spergualin as active ingredient and process for preparing the same

Info

Publication number
CA1263316A
CA1263316A CA000499451A CA499451A CA1263316A CA 1263316 A CA1263316 A CA 1263316A CA 000499451 A CA000499451 A CA 000499451A CA 499451 A CA499451 A CA 499451A CA 1263316 A CA1263316 A CA 1263316A
Authority
CA
Canada
Prior art keywords
spergualin
dione
amino
hydroxy
guanidino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000499451A
Other languages
English (en)
French (fr)
Inventor
Hamao Umezawa
Shintaro Suzuki
Taka'aki Ohkuma
Fumihiro Sato
Teruya Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Application granted granted Critical
Publication of CA1263316A publication Critical patent/CA1263316A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA000499451A 1985-01-14 1986-01-13 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same Expired CA1263316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP60003351A JPS61165322A (ja) 1985-01-14 1985-01-14 スパガリン類の注射用凍結乾燥製剤
JP3351/85 1985-01-14

Publications (1)

Publication Number Publication Date
CA1263316A true CA1263316A (en) 1989-11-28

Family

ID=11554927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000499451A Expired CA1263316A (en) 1985-01-14 1986-01-13 Medical composition for injection containing a spergualin as active ingredient and process for preparing the same

Country Status (10)

Country Link
US (2) US4710517A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0188821B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS61165322A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR920003331B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1010279B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE55246T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU589939B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1263316A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3579146D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE58220B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869734A (en) * 1995-09-26 1999-02-09 Bristol-Myers Squibb Co. Preparation of optically active (S)-(-) and (R)-(+)-deoxyspergualin and novel intermediates thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61129119A (ja) * 1984-11-13 1986-06-17 Microbial Chem Res Found 新規免疫抑制剤
ES2039213T3 (es) * 1986-04-04 1993-09-16 Microbial Chemistry Research Foundation Procedimiento para producir nuevos compuestos relacionados con espergualina.
CA1330650C (fr) * 1987-10-22 1994-07-12 Alain Huc Procede de stabilisation de phases lamellaires lipidiques hydratees, par exemple de liposomes, composition de phases lamellaires lipidiques hydratees, par exemple des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes, et utilisation en pharmacie ou en ...
FR2622104B1 (fr) * 1987-10-22 1990-03-30 Bioetica Sa Procede de stabilisation de phases lamellaires lipidiques hydratees, par ex. de liposomes, composition de phases lamellaires lipidiques hydratees, par ex. des liposomes, stabilisees par un emploi d'un support stabilisant a base d'atelocollagene et de glycosaminoglycannes et utilisation en pharmacie ou en cosmetologie
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
WO1989006536A1 (en) * 1988-01-19 1989-07-27 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5637575A (en) * 1988-01-19 1997-06-10 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
AU626538B2 (en) * 1988-01-19 1992-08-06 Moses Judah Folkman Growth inhibiting agent and the use thereof
US5002756A (en) * 1988-04-04 1991-03-26 Zaidanhojin Biseibutsu Kagakukenkyukai Method for relieving radiogenic or drug-induced side effects
DE69000194T2 (de) * 1988-12-02 1993-01-14 Coletica Stabilisierung von hydratierten lamellaren phasen.
EP0420964A4 (en) * 1989-04-11 1991-09-25 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
US5441944A (en) * 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
US5424301A (en) * 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
CA2159717A1 (en) * 1993-03-31 1994-10-13 Elliot Barnathan Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
EP0986403B1 (en) * 1997-06-13 2003-11-12 Cydex Inc. Composition with extended shelf-life storage comprising cyclodextrin and drugs or prodrugs that decompose to water-insoluble components
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
CN1556712A (zh) * 2000-07-13 2004-12-22 ��һ��������ҩ��ʽ���� 含dds化合物的药用组合物
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54157818A (en) * 1978-06-02 1979-12-13 Tokyo Tanabe Co Injectionable preparation of chlorethylnitrosourea compound
JPS5748957A (en) * 1980-09-08 1982-03-20 Microbial Chem Res Found Novel antibiotic bmg 162-af2, its preparation and carcinostatic agent comprising it as active ingredient
JPS57185254A (en) * 1981-05-11 1982-11-15 Microbial Chem Res Found Novel carcinostatic substances and their preparation
JPS5862152A (ja) * 1981-10-08 1983-04-13 Microbial Chem Res Found Ｎ−〔４−（３−アミノプロピル）アミノブチル〕−２−（ω−グアニジノ脂肪酸アミド）−２−ヒドロキシエタンアミドおよびその誘導体ならびにその製造法
JPS58198455A (ja) * 1982-05-17 1983-11-18 Microbial Chem Res Found （−）−１５−デオキシスパガリンおよびその製造法並びにその中間体
JPS5942356A (ja) * 1982-09-02 1984-03-08 Microbial Chem Res Found スパガリン関連化合物およびその製造法
US4525299A (en) * 1983-05-10 1985-06-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (-)-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same
JPS60185758A (ja) * 1984-03-02 1985-09-21 Microbial Chem Res Found フエニレン基を有するスパガリン関連化合物およびその製造法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869734A (en) * 1995-09-26 1999-02-09 Bristol-Myers Squibb Co. Preparation of optically active (S)-(-) and (R)-(+)-deoxyspergualin and novel intermediates thereof

Also Published As

Publication number Publication date
DE3579146D1 (de) 1990-09-13
IE860089L (en) 1986-07-14
JPH0413325B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-03-09
US4876244A (en) 1989-10-24
ATE55246T1 (de) 1990-08-15
KR860005636A (ko) 1986-08-11
EP0188821A2 (en) 1986-07-30
CN86100157A (zh) 1986-08-27
KR920003331B1 (ko) 1992-04-27
JPS61165322A (ja) 1986-07-26
CN1010279B (zh) 1990-11-07
AU5222486A (en) 1986-07-17
AU589939B2 (en) 1989-10-26
IE58220B1 (en) 1993-08-11
EP0188821B1 (en) 1990-08-08
US4710517A (en) 1987-12-01
EP0188821A3 (en) 1987-08-12

Similar Documents

Publication Publication Date Title
CA1263316A (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
CA2111560A1 (en) Stable pharmaceutical composition of fumagillol derivatives
AU575153B2 (en) Pharmaceutical compositions and method for treatment for prophylaxis of cardiac disorders
EP2865391B1 (de) Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C
AU709785B2 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
IE51637B1 (en) Pharmaceutical preparation
PL178522B1 (pl) Krystaliczny, bezwodny związek, mykofenolan mofetylu, kompozycja odpowiednia do sporządzania wodnego preparatu dożylnego, sposób wytwarzania kompozycji odpowiedniej do sporządzania preparatu dożylnego i zestaw użyteczny do sporządzania dożylnego preparatu
EP0298192A1 (en) Stable, injectable solutions of vincristine salts
CA2208484C (en) Soluble 2-chloro-2'-deoxyadenosine formulations
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
US20060089328A1 (en) Ready-to-use gemcitabine solutions
JPH06510042A (ja) ロイコトリエンレセプター拮抗剤−抗ヒスタミン剤複合体
KR20030016426A (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
CN115737571B (zh) 一种喷他佐辛制剂及其制备方法和用途
US5093127A (en) Preparation of fr115224 substrate for parenteral administration
US4344950A (en) Parenteral solvent and a process for the preparation of stable solutions containing same
US4600583A (en) Pharmaceutical compositions
US20060089329A1 (en) Ready-to-use gemcitabine solution concentrates
WO2025165852A1 (en) Liquid formulations of lurbinectedin
US4882356A (en) Stable injectable antiemetic compositions
CA2208241C (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
EP1479388A1 (de) Gebrauchsfertige Gemcitabin-Lösungskonzentrate
EA016861B1 (ru) Стабильные составы на основе производного тиадиазола
CN104856947A (zh) 一种前列地尔的羟丙基-α-环糊精包合物注射剂
JPS61267523A (ja) 安定な注射組成物およびそれらの製造方法

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205